middle.news
How Will BCAL’s $10M Convertible Note Propel Cancer Test Commercialisation?
8:43am on Monday 20th of October, 2025 AEDT
•
Biotechnology
Read Story
How Will BCAL’s $10M Convertible Note Propel Cancer Test Commercialisation?
8:43am on Monday 20th of October, 2025 AEDT
Key Points
Convertible note facility up to $10 million for working capital
Firm commitments received for $5 million pending legal finalisation
Facility subject to shareholder approval at November 26 AGM
10% annual interest with 2-year maturity and conversion discounts
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Bcal Diagnostics (ASX:BDX)
OPEN ARTICLE